J&J Targets Disease Management, Touts “Enlightened Decentralization”
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson is moving toward a business model focused on offering "product solutions" for the healthcare system, Biopharmaceuticals Group Chairman Joseph Scodari told the Wharton Health Care Business Conference Feb. 19 in Philadelphia